Invesaro

Stocks Health care EMED

OTC · Health care

Electromedical Technologies, Inc (EMED)

Electromedical Technologies, Inc brought in $922K of revenue over the twelve months to September 30, 2024, down 35.1% from a year earlier. It posted a net loss of $1.7M. In fiscal 2023 capital spending exceeded operating cash flow by $1.6M. At September 30, 2024 it held $34.8K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 19, 2024.

Watch EMED in 60 seconds
Price
$0.00
0.00% on the day · September 25, 2026
52-week range $0.00 to $0.00
Market cap
$85.5K
Revenue (last 12 months)
$922K
-35.1% year on year
Net margin
-182.0%

What Electromedical Technologies, Inc does

Electromedical Technologies, Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker EMED.

Revenue and profit by year

Revenue
FY20: $829.7K $829.7K FY20FY20: $738K $738K FY20FY21: $907.4K $907.4K FY21FY22: $1.1M $1.1M FY22FY23: $1.3M $1.3M FY23
Net income
FY20: -$1.7M -$1.7M FY20FY20: -$3.9M -$3.9M FY20FY21: -$8.5M -$8.5M FY21FY22: -$3.5M -$3.5M FY22FY23: -$2.6M -$2.6M FY23

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2023$1.3M-$2.1M-$2.6M$0.00-$1.6M
2022$1.1M-$1.6M-$3.5M-$0.03n/a
2021$907.4K-$3.8M-$8.5M-$0.24n/a
2020$738K-$3.2M-$3.9M-$0.20n/a
2020$829.7K-$1.7M-$1.7M-$0.12n/a

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Electromedical Technologies, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. July 14, 2025
  2. March 31, 2025
  3. November 19, 2024
    Quarterly report 10-Q · period to September 30, 2024Revenue fell 87% to $42.5K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  4. November 14, 2024
  5. October 16, 2024
    Annual report (amended) 10-K/A · period to December 31, 2023Revenue rose 17% to $1.3M versus the prior year; diluted EPS $0.00 versus -$0.03.
  6. August 14, 2024
    Quarterly report 10-Q · period to June 30, 2024Revenue fell 19% to $237.6K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
  7. August 9, 2024
  8. July 24, 2024
  9. June 14, 2024
    Quarterly report 10-Q · period to March 31, 2024Revenue fell 23% to $290.2K versus the same quarter last year; diluted EPS -$0.00 versus -$0.00.
  10. May 21, 2024

Recent insider filings (Forms 3, 4 and 144): 10, the latest on February 10, 2023. Insider transactions on SEC

All filings on SEC EDGAR

Questions about EMED

What does Electromedical Technologies, Inc do?

Electromedical Technologies, Inc is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on OTC under the ticker EMED.

Is Electromedical Technologies, Inc profitable?

No. Over the twelve months to September 30, 2024 it reported a net loss of $1.7M on revenue of $922K.

How much revenue does Electromedical Technologies, Inc make?

Over the twelve months to September 30, 2024 Electromedical Technologies, Inc reported revenue of $922K. That is 35.1% less than a year earlier.

When did Electromedical Technologies, Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 19, 2024. It covers the period to September 30, 2024. Its newest filing of any kind is the deregistration from July 14, 2025.

Similar companies

Compare EMED with

Compare EMED with any company

Follow EMED

Get an email when Electromedical Technologies, Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow EMED: get an email when it files

Where the numbers come from

Financial figures are the values Electromedical Technologies, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.